Page last updated: 2024-12-07

3'-o-methyl-nordihydroguaiaretic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

heminordihydroguaiaretic acid: RN given refers to cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122821
CHEMBL ID400065
SCHEMBL ID13309003
MeSH IDM0125111

Synonyms (19)

Synonym
(+)-4-[4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]-benzene-1,2-diol
(+/-)-4-[4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]-benzene-1,2-diol
mal.4
3-o'-methyl-ndga
54473-24-4
1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)-2,3dimethylbutane
3-o'-methyl nordihydroguaiaretic acid
4-[(2r,3s)-4-(4-hydroxy-3-methoxy-phenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
heminordihydroguaiaretic acid
CHEMBL400065
1,2-benzenediol, 4-(4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl)-
hemi-ndga
3'-o-methyl-nordihydroguaiaretic acid
malachi 4 5-6
3'-o-methyl-ndga
SCHEMBL13309003
QKHJBWUGXMKHAK-OLZOCXBDSA-N
4-[4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DTXSID60969644
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID313419Antioxidant activity assessed as inhibition of LDL-oxidation at 20 uM by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID313420Antioxidant activity against LDL-oxidation by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]